Neoplasia/BPH

	Prospective head-to-head comparison of [(68)Ga]Ga-RM2 PET/CT and [(68)Ga]Ga-PSMA-617 PET/CT in newly diagnosed patients with intermediate-risk localized prostate cancer. Eur J Nucl Med Mol Imaging Perozziello F, Robert G, Meyer M, Jambon E, Bladou F, Yacoub M, Lamare F, Vimont D, Balamoutoff N, Hindié E, Morgat C. PMID: 41656418 [PubMed - as supplied by publisher]
	[(68)Ga]Ga-NY104 PET/CT and [(18)F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial. Eur J Nucl Med Mol Imaging Yan X, Li X, Zheng G, Ma M, Liu M, Wang J, Zhang Y, Ba Y, Gao X, Zhu W, Huo L. PMID: 41656417 [PubMed - as supplied by publisher]
	Percutaneous Biopsy and Recurrence Risk in Stage 1 Renal Cancer: A Propensity Score-Matched Cohort Study. Ann Surg Oncol Yoo JH, Song M, Sung JW, Suh J, Kim JK, Kim M, Park KJ, Song C. PMID: 41656407 [PubMed - as supplied by publisher]
	Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: a systematic review. Crit Rev Oncol Hematol Abu-Ghanem Y, , Chan HT, Krajewski W, Chung BI, Corvino R, Santarelli V, Khan A, Crocetto F, Ibrahim Y, Gad M, Kirmani SGA, Spurna K, Challacombe B, Nair R, Mensah E, Thuraraja R, Khan MS, Del Giudice F. PMID: 41655753 [PubMed - as supplied by publisher]
	Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol Nilsson P, Gunnlaugsson A, Beckman L, Widmark A, Fransson P, Hoyer M, Lagerlund M, Kindblom J, Johansson B, Björnlinger K, Ginman C, Olsson M, Agrup M, Kjellén E, Zackrisson B, Tavelin B, Franzén L, Anderson H, Thellenberg Karlsson C. PMID: 41655576 [PubMed - as supplied by publisher]
	Patient awareness and perspectives regarding the value of focal therapy for localized prostate cancer: A cross-sectional study. Urol Oncol Yasinzai AK, Smith J, Lertkitcharoenpo A, Bourricaudy RA, Chang JJ, Stringer TF, DiBianco JM, Joseph JP, O'Malley P, Crispen PL, Su LM, Benidir T. PMID: 41655341 [PubMed - as supplied by publisher]
	Monitoring cancer-related fatigue and quality of life in breast and prostate cancer patients after primary treatment: a study protocol for the REBECCA trials in Norway. Clin Exp Med Stensland M, Bru KF, Austdal M, Dahl IH, Jonsdottir K, Lende TH, Heimvik C, Elve I, Omdal R, van der Giezen M, Kvivik I, Tangeland B, Davidsen L, Hashemi M, Cais A, van Dijk KJ, Seyoum Y, Blåfjelldal V, Sola ST, Papadopoulos A, Kiriakidou N, Ioakeimidis I, Diou C, Sarafis I, Delopoulos A, Janssen EAM, Gilje B, Tjensvoll K. PMID: 41655181 [PubMed - as supplied by publisher]
	Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. Sci Rep Li S, Qin J, Sun Q, Zhao H, Xiong Y, Wang Y, Han Y, Zhang J, Zhang W, Shen M, Yang F, Ren B, Zhou L, Li R, Hui Z, Tian X, Cao S, Du W, Yu W, Liu L, Zhang X, Ren X. PMID: 41654611 [PubMed - as supplied by publisher]
	Statin use and outcomes in advanced prostate cancer:Secondary analysis of the SPARTAN trial. Urol Oncol Mousa A, Chavarriaga J, Lajkosz K, Penn LZ, Khurram N, Hamilton RJ. PMID: 41654482 [PubMed - as supplied by publisher]
	Predicting Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Model Development and Evaluation in an International Cohort Study. Clin Genitourin Cancer Weiner AB, Martin SC, Wilhalme H, Bailey AV, Kwan L, Awamlh BAHA, Zhao Z, Verze P, Ippolito J, La Rocca R, Sibert NT, Barocas DA, Belin TR, Elashoff D, Kowalski C, Foster C, Moore C, Litwin MS, True North Global Registry. PMID: 41654456 [PubMed - as supplied by publisher]
	Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol Contieri R, Paciotti M, Uleri A, Saita A, Taverna G, Sedigh O, Barra S, Colombo P, Porreca A, Beatrici E, Fasulo V, Avolio PP, Frego N, Finocchiaro A, Cella L, Collura D, Cieri M, Guazzoni G, Buffi NM, Lughezzani G, Casale P, Lazzeri M, Hurle R. PMID: 41654427 [PubMed - as supplied by publisher]
	Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in Spain. Clin Transl Oncol Romero Zoghbi SE, López Campos F, Ocanto A, Sanz-Rosa D, Thuissard-Vasallo IJ, Andreu Vázquez C, Laria C, Fernández Ibiza J, Andreescu Yagüe J, Krumina E, Mateos M, Dzhugashvili M, Glaría LA, Gonsalves D, Fernández C, Esteban D, de la Fuente JB, González Ferreira JA, Ristori A, Rivas D, López E, Bezares Alarcón AB, Aakki L, Larrea L, García Cuesta JÁ, Zamboglou C, Alongi F, García García R, Couñago F. PMID: 41653361 [PubMed - as supplied by publisher]
	Kidney cancer and occupational agricultural exposures in the AGRIculture and CANcer cohort. Int J Epidemiol Nassar C, Boulanger M, Baldi I, Tual S, Bara S, Lebailly P, Clin B, AGRICAN group. PMID: 41653060 [PubMed - indexed for MEDLINE]
	The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor. Cancer Cell Int Ye M, Badehnoosh B. PMID: 41652619 [PubMed - as supplied by publisher]
	A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives. Pharmacoeconomics Darbà J, Ascanio M, Rodríguez A. PMID: 41652274 [PubMed - as supplied by publisher]
	Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study. Eur Radiol Englman C, Adebusoye B, Cosenza M, Del Prete A, Dickinson L, Imperiale G, Leni R, Gandaglia G, De Cobelli F, Mallett S, Kirkham A, Moore CM, Giganti F, Brembilla G. PMID: 41652236 [PubMed - as supplied by publisher]
	Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study. Br J Cancer Blanchet B, Puszkiel A, Jouinot A, Bennamoun M, Maillet D, Borchiellini D, Laguerre B, Pannier D, Gross-Goupil M, Chevreau C, Barthélémy P, Tournigand C, Coquan E, Gravis G, Lepicard E, Fridman WH, Sautes-Fridman C, Oudard S, Sun CM, Vano YA. PMID: 41652222 [PubMed - as supplied by publisher]
	Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer. Brachytherapy Xue A, Wang L, Akerman M, Gogineni A, Coelho A, Potters L, Parashar B. PMID: 41651735 [PubMed - as supplied by publisher]
	Diagnostic performance of urinary biomarker tests in detecting bladder cancer: A systematic review, meta-analysis, and network meta-analysis. Urology Siguencia F, Heard J, Smith SM, Pagano I, Furuya H, Wu X, Ahdoot M, Rosser CJ. PMID: 41651230 [PubMed - as supplied by publisher]
	Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program. Am J Hum Genet Cheng S, Suger AH, Goss LB, Zhang J, Fuller H, Guo B, Lindström S, Darst BF. PMID: 41650938 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 185315

Page 1 of 9266



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy